Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS), affect millions of people worldwide.
Neurodegenerative diseases occur when nerves in the central nervous system (CNS) lose function over time and die, resulting in a loss of specific brain functions, such as memory, movement, and cognition.
SalubrisBio's first neurology-focused clinical trial will evaluate JK07 in ALS and is expected to initiate in 2024.
ALS is a progressive neurodegenerative diseases that affects nerves cells in the brain and spinal cord that causes muscle weakness paralysis and, eventually, respiratory failure. It is a rare disease with an incidence of about 5,000 new cases diagnosed annually in the U.S.1 There is no cure for ALS and the average life expectancy is typically 2 to 5 years from the time of diagnosis.2
Check back soon for more details on this clinical trial.